AFT Pharmaceuticals (NZE:AFT, ASX:AFP) remains on course to deliver its fiscal 2027 revenue target of NZ$300 million and operating profit guidance of NZ$28 million to NZ$32 million, supported by double-digit first-half revenue growth across all divisions, according to a Tuesday filing with the Australian and New Zealand bourses.

Key developments include the out-licensing of Maxigesic IV in Japan and the Philippines; positive phase one vaccine results published in The Lancet, further validating StablePharma's fridge-free medicine technology; and tentative US Food and Drug Administration approval for Scomara, marking the company's third patented product approval in the US, per the filing.

The company has also launched Maxigesic Rapid in the US through Mark Cuban's Cost Plus Drugs, while its Feramyl IV injectable iron product has entered a large-scale clinical study involving 1,366 patients, the filing said.

The fiscal 2027 research and development spending is expected to reach NZ$23 million to NZ$25 million, supporting the development of eight pipeline drugs, continued product launches, and growth across international markets, the filing added.

The company's New Zealand shares were up nearly 2% in recent Tuesday trade.